Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmed Pharmaceuticals Inc (NQ: INM )

0.3429 -0.0019 (-0.55%)
Streaming Delayed Price Updated: 3:18 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 391,257
Open 0.3363
Bid (Size) 0.3405 (11)
Ask (Size) 0.3453 (242)
Prev. Close 0.3448
Today's Range 0.3363 - 0.3574
52wk Range 0.1207 - 2.080
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901
Via Investor Brand Network

Performance

YTD
-12.08%
-12.08%
1 Month
+54.11%
+54.11%
3 Month
+13.92%
+13.92%
6 Month
-17.37%
-17.37%
1 Year
-61.03%
-61.03%

More News

Read More
Why Wolfspeed Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Three U.S. Patent Issuances
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Crude Oil Falls; Palo Alto Networks Shares Jump After Q4 Earnings
Via Benzinga
Exposures Fossil Fuels
Nasdaq Moves Lower; Medtronic Posts Upbeat Earnings
Via Benzinga
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment
Via Investor Brand Network
InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday
Via Benzinga
US Stocks Mixed; Lowe's Cuts FY24 Forecast
Via Benzinga
BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD
Via Investor Brand Network
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Via Investor Brand Network
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Via CannabisNewsWire
The Rising Importance Of Minor Cannabinoids In The Growing Edible Market
Via News Direct
Topics Cannabis
Exposures Cannabis
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment
Via Investor Brand Network
7 F-Rated Growth Stocks to Avoid Right Now: June 2024
Via InvestorPlace
InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation at Upcoming Emerging Growth Conference
Via Investor Brand Network
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
INM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.